Yoda Pharmaceuticals Inc.

Yoda Pharmaceuticals Inc. is an AI-driven company focused on developing drugs for central nervous system disorders. Its flagship drug, YA-101, is in Phase 2 clinical trials for the treatment of multiple system atrophy. Its development pipeline also includes drugs for neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions such as schizophrenia, Alzheimer's disease, Parkinson's disease, autism, ischemic stroke, and traumatic brain injury. Incorporated in 2019, the company is based in Grand Cayman, the Cayman Islands.